Purpose: TPN has been widely used to treat nutritional depletion since the late 1960s. However, many metabolic complications may occur as a result of parenteral feeding. Among these, hepatic complications has received increasing attention.
A
retrospective review of liver function abnormalities in adult patients who underwent TPN was done to determine the frequency and magnitude of the abnormalities in a liver function test.
Methods: From January 2001 to Jun 2001, 160 adult patient receiving TPN were reviewed. Of these, 111 had a malignant disease and 49 had a benign disease. The duration of TPN therapy ranged from 5 days to 52 days, with a mean duration of 14
days.
Abnormalities of liver function test were defined as a value greater than the upper normal limit. Forty cases of gastric cancer were analyzed to determine the risk factors that contribute to abnormal liver function in individual patients
receiving
TPN.
Results: Abnormalities of the liver function test appeared after 6∼7 days of therapy. Increases in the ALP levels were noted in 34 out of 93 patients (37.6%), in the AST levels in 42 out of 116 patients (36.2%), in the ALT levels in 54 out
of
125 patients (43.2%), in the LDH levels in 20 out of 72 patients (27.8%), in the γ-GTP levels in 44 out of 81 patients (54.3%), and in the bilirubin levels in 30 out of 126 patients (23.8%). The serum ALP level rose to 1.6 times upper the limit
of
normal; AST, 1.7 times; ALT, 2.0 times; LDH, 1.2 times; γ-GTP, 2.4 times; bilirubin, 2.4 times. γ-GTP value was most sensitive. In 40 gastric cancers, factors as age, the amount of TPN solution, the duration of TPN, intraoperative chemotherapy,
transfusion, and postoperative infection were investigated. However, no association with TPN-associated liver function abnormalities was found.
Conclusion: The incidences of an abnormal liver function during TPN were 23.8∼54.3%. However, the liver function abnormalities that developed during short term-TPN were reversible and not serious.
|